Strs Ohio boosted its stake in shares of BioTelemetry, Inc. (NASDAQ:BEAT) by 126.0% during the second quarter, Holdings Channel reports. The firm owned 61,700 shares of the medical research company’s stock after buying an additional 34,400 shares during the period. Strs Ohio’s holdings in BioTelemetry were worth $2,063,000 as of its most recent filing with the SEC.
Other large investors have also recently bought and sold shares of the company. Dubuque Bank & Trust Co. purchased a new stake in BioTelemetry during the second quarter valued at approximately $142,000. US Bancorp DE bought a new stake in shares of BioTelemetry during the second quarter valued at about $145,000. FNY Partners Fund LP bought a new stake in shares of BioTelemetry during the first quarter valued at about $142,000. State of Alaska Department of Revenue raised its stake in shares of BioTelemetry by 80.1% in the second quarter. State of Alaska Department of Revenue now owns 5,638 shares of the medical research company’s stock valued at $188,000 after buying an additional 2,508 shares during the last quarter. Finally, Mason Street Advisors LLC raised its stake in shares of BioTelemetry by 7.5% in the first quarter. Mason Street Advisors LLC now owns 6,634 shares of the medical research company’s stock valued at $192,000 after buying an additional 465 shares during the last quarter. Hedge funds and other institutional investors own 83.91% of the company’s stock.
Shares of BioTelemetry, Inc. (BEAT) opened at 33.75 on Friday. The stock’s 50 day moving average is $33.38 and its 200 day moving average is $29.11. BioTelemetry, Inc. has a 52 week low of $15.25 and a 52 week high of $36.50. The stock has a market cap of $970.11 million, a price-to-earnings ratio of 22.55 and a beta of 0.76.
BioTelemetry (NASDAQ:BEAT) last released its quarterly earnings data on Tuesday, August 8th. The medical research company reported $0.23 earnings per share for the quarter, beating the consensus estimate of $0.21 by $0.02. BioTelemetry had a net margin of 21.03% and a return on equity of 18.75%. The firm had revenue of $58.10 million during the quarter, compared to analysts’ expectations of $58.39 million. During the same period in the previous year, the company earned $0.20 earnings per share. The firm’s quarterly revenue was up 10.2% on a year-over-year basis. On average, equities analysts forecast that BioTelemetry, Inc. will post $0.92 EPS for the current year.
TRADEMARK VIOLATION WARNING: This article was originally published by Ticker Report and is the property of of Ticker Report. If you are viewing this article on another publication, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this article can be read at https://www.tickerreport.com/banking-finance/2801495/strs-ohio-has-2-06-million-position-in-biotelemetry-inc-beat.html.
BEAT has been the subject of several research analyst reports. Zacks Investment Research upgraded shares of BioTelemetry from a “hold” rating to a “buy” rating and set a $38.00 price target for the company in a research note on Tuesday, May 2nd. Benchmark Co. raised their price target on shares of BioTelemetry from $38.00 to $44.00 and gave the stock a “buy” rating in a research note on Wednesday, July 19th. Lake Street Capital restated a “buy” rating and set a $50.00 price target (up previously from $35.00) on shares of BioTelemetry in a research note on Friday, July 14th. BidaskClub lowered shares of BioTelemetry from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 25th. Finally, Dougherty & Co raised their price target on shares of BioTelemetry from $37.00 to $40.00 and gave the stock a “buy” rating in a research note on Wednesday. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $44.20.
In other news, Director Robert J. Rubin sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, May 15th. The shares were sold at an average price of $28.14, for a total transaction of $422,100.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 9.60% of the stock is owned by insiders.
BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.
Want to see what other hedge funds are holding BEAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioTelemetry, Inc. (NASDAQ:BEAT).
Receive News & Ratings for BioTelemetry Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry Inc. and related companies with MarketBeat.com's FREE daily email newsletter.